| Alexander J Fernandez, MD | |
|
2125 Crystal Grove Dr, Lakeland, FL 33801-6875 | |
| (863) 688-2334 | |
| Not Available |
| Full Name | Alexander J Fernandez |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 24 Years |
| Location | 2125 Crystal Grove Dr, Lakeland, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063639342 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | ME103779 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Louis A Weiss Memorial Hospital | Chicago, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Radiology Imaging Specialists Llc | 0244529030 | 15 |
| Amin Radiology Inc | 3072503788 | 13 |
| West Hernando Diagnostic And Mr Center, Inc | 4880653195 | 21 |
| Ocala Family Medical Center Inc | 6608865290 | 54 |
| Resilience Healthcare - Lakefront Medical Associates Llc | 5991046468 | 45 |
News Archive
Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach , usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of "The Oncologist."
Professor David Nutt is aiming to make hangovers a thing of the past by introducing a synthetic alcohol alternative named "alcosynth".
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer.
Analysis from business intelligence provider GBI Research - Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - states that the Colorectal Cancer (CRC) treatment market value will increase at a moderate Compound Annual Growth Rate (CAGR) of 1.8%, from $8.3 billion in 2013 to $9.4 billion by 2020.
› Verified 8 days ago
| Entity Name | Community Health Of South Florida Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336152347 PECOS PAC ID: 6507770526 Enrollment ID: O20031118000460 |
News Archive
Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach , usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of "The Oncologist."
Professor David Nutt is aiming to make hangovers a thing of the past by introducing a synthetic alcohol alternative named "alcosynth".
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer.
Analysis from business intelligence provider GBI Research - Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - states that the Colorectal Cancer (CRC) treatment market value will increase at a moderate Compound Annual Growth Rate (CAGR) of 1.8%, from $8.3 billion in 2013 to $9.4 billion by 2020.
› Verified 8 days ago
| Entity Name | University Diagnostic Institute Winter Park Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417917253 PECOS PAC ID: 5991607871 Enrollment ID: O20040122000010 |
News Archive
Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach , usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of "The Oncologist."
Professor David Nutt is aiming to make hangovers a thing of the past by introducing a synthetic alcohol alternative named "alcosynth".
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer.
Analysis from business intelligence provider GBI Research - Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - states that the Colorectal Cancer (CRC) treatment market value will increase at a moderate Compound Annual Growth Rate (CAGR) of 1.8%, from $8.3 billion in 2013 to $9.4 billion by 2020.
› Verified 8 days ago
| Entity Name | Orlando Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669429577 PECOS PAC ID: 9537059084 Enrollment ID: O20040318000044 |
News Archive
Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach , usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of "The Oncologist."
Professor David Nutt is aiming to make hangovers a thing of the past by introducing a synthetic alcohol alternative named "alcosynth".
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer.
Analysis from business intelligence provider GBI Research - Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - states that the Colorectal Cancer (CRC) treatment market value will increase at a moderate Compound Annual Growth Rate (CAGR) of 1.8%, from $8.3 billion in 2013 to $9.4 billion by 2020.
› Verified 8 days ago
| Entity Name | Ocala Family Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871589192 PECOS PAC ID: 6608865290 Enrollment ID: O20040510000265 |
News Archive
Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach , usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of "The Oncologist."
Professor David Nutt is aiming to make hangovers a thing of the past by introducing a synthetic alcohol alternative named "alcosynth".
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer.
Analysis from business intelligence provider GBI Research - Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - states that the Colorectal Cancer (CRC) treatment market value will increase at a moderate Compound Annual Growth Rate (CAGR) of 1.8%, from $8.3 billion in 2013 to $9.4 billion by 2020.
› Verified 8 days ago
| Entity Name | Amin Radiology Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700873981 PECOS PAC ID: 3072503788 Enrollment ID: O20040514000793 |
News Archive
Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach , usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of "The Oncologist."
Professor David Nutt is aiming to make hangovers a thing of the past by introducing a synthetic alcohol alternative named "alcosynth".
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer.
Analysis from business intelligence provider GBI Research - Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - states that the Colorectal Cancer (CRC) treatment market value will increase at a moderate Compound Annual Growth Rate (CAGR) of 1.8%, from $8.3 billion in 2013 to $9.4 billion by 2020.
› Verified 8 days ago
| Entity Name | Advanced Imaging Concepts Pl |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215991815 PECOS PAC ID: 5597704627 Enrollment ID: O20050428000431 |
News Archive
Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach , usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of "The Oncologist."
Professor David Nutt is aiming to make hangovers a thing of the past by introducing a synthetic alcohol alternative named "alcosynth".
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer.
Analysis from business intelligence provider GBI Research - Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - states that the Colorectal Cancer (CRC) treatment market value will increase at a moderate Compound Annual Growth Rate (CAGR) of 1.8%, from $8.3 billion in 2013 to $9.4 billion by 2020.
› Verified 8 days ago
| Entity Name | West Hernando Diagnostic And Mr Center, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831183607 PECOS PAC ID: 4880653195 Enrollment ID: O20060808000086 |
News Archive
Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach , usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of "The Oncologist."
Professor David Nutt is aiming to make hangovers a thing of the past by introducing a synthetic alcohol alternative named "alcosynth".
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer.
Analysis from business intelligence provider GBI Research - Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - states that the Colorectal Cancer (CRC) treatment market value will increase at a moderate Compound Annual Growth Rate (CAGR) of 1.8%, from $8.3 billion in 2013 to $9.4 billion by 2020.
› Verified 8 days ago
| Entity Name | Partners Imaging Center Of Sarasota Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548205271 PECOS PAC ID: 0042217861 Enrollment ID: O20061108000417 |
News Archive
Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach , usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of "The Oncologist."
Professor David Nutt is aiming to make hangovers a thing of the past by introducing a synthetic alcohol alternative named "alcosynth".
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer.
Analysis from business intelligence provider GBI Research - Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - states that the Colorectal Cancer (CRC) treatment market value will increase at a moderate Compound Annual Growth Rate (CAGR) of 1.8%, from $8.3 billion in 2013 to $9.4 billion by 2020.
› Verified 8 days ago
| Entity Name | Ohri Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386034346 PECOS PAC ID: 4981912169 Enrollment ID: O20151008000809 |
News Archive
Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach , usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of "The Oncologist."
Professor David Nutt is aiming to make hangovers a thing of the past by introducing a synthetic alcohol alternative named "alcosynth".
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer.
Analysis from business intelligence provider GBI Research - Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - states that the Colorectal Cancer (CRC) treatment market value will increase at a moderate Compound Annual Growth Rate (CAGR) of 1.8%, from $8.3 billion in 2013 to $9.4 billion by 2020.
› Verified 8 days ago
| Entity Name | Radiology Imaging Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952763971 PECOS PAC ID: 0244529030 Enrollment ID: O20160518000804 |
News Archive
Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach , usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of "The Oncologist."
Professor David Nutt is aiming to make hangovers a thing of the past by introducing a synthetic alcohol alternative named "alcosynth".
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer.
Analysis from business intelligence provider GBI Research - Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - states that the Colorectal Cancer (CRC) treatment market value will increase at a moderate Compound Annual Growth Rate (CAGR) of 1.8%, from $8.3 billion in 2013 to $9.4 billion by 2020.
› Verified 8 days ago
| Entity Name | Zwanger & Pesiri Radiology Group Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477523413 PECOS PAC ID: 5092700799 Enrollment ID: O20171219003012 |
News Archive
Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach , usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of "The Oncologist."
Professor David Nutt is aiming to make hangovers a thing of the past by introducing a synthetic alcohol alternative named "alcosynth".
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer.
Analysis from business intelligence provider GBI Research - Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - states that the Colorectal Cancer (CRC) treatment market value will increase at a moderate Compound Annual Growth Rate (CAGR) of 1.8%, from $8.3 billion in 2013 to $9.4 billion by 2020.
› Verified 8 days ago
| Entity Name | Valley Imaging Consultants Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215987045 PECOS PAC ID: 6800882374 Enrollment ID: O20180509000889 |
News Archive
Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach , usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of "The Oncologist."
Professor David Nutt is aiming to make hangovers a thing of the past by introducing a synthetic alcohol alternative named "alcosynth".
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer.
Analysis from business intelligence provider GBI Research - Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - states that the Colorectal Cancer (CRC) treatment market value will increase at a moderate Compound Annual Growth Rate (CAGR) of 1.8%, from $8.3 billion in 2013 to $9.4 billion by 2020.
› Verified 8 days ago
| Entity Name | Shps Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790421089 PECOS PAC ID: 7315325933 Enrollment ID: O20220820000378 |
News Archive
Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach , usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of "The Oncologist."
Professor David Nutt is aiming to make hangovers a thing of the past by introducing a synthetic alcohol alternative named "alcosynth".
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer.
Analysis from business intelligence provider GBI Research - Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - states that the Colorectal Cancer (CRC) treatment market value will increase at a moderate Compound Annual Growth Rate (CAGR) of 1.8%, from $8.3 billion in 2013 to $9.4 billion by 2020.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alexander J Fernandez, MD 2125 Crystal Grove Dr, Lakeland, FL 33801-6875 Ph: (863) 688-2334 | Alexander J Fernandez, MD 2125 Crystal Grove Dr, Lakeland, FL 33801-6875 Ph: (863) 688-2334 |
News Archive
Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach , usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of "The Oncologist."
Professor David Nutt is aiming to make hangovers a thing of the past by introducing a synthetic alcohol alternative named "alcosynth".
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer.
Analysis from business intelligence provider GBI Research - Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - states that the Colorectal Cancer (CRC) treatment market value will increase at a moderate Compound Annual Growth Rate (CAGR) of 1.8%, from $8.3 billion in 2013 to $9.4 billion by 2020.
› Verified 8 days ago
Dr. Kevin James Sawyer, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2125 Crystal Grove Dr, Lakeland, FL 33801 Phone: 863-688-2334 | |
Dr. Yelena Kozirovsky, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1420 Lakeland Hills Blvd, Lakeland, FL 33805 Phone: 863-680-7000 Fax: 866-264-8519 | |
Dr. Michael Larone Campbell, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1305 Lakeland Hills Blvd, Lakeland, FL 33805 Phone: 863-688-2334 | |
Michael K Gordon, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 2115 Crystal Grove Dr, Lakeland, FL 33801 Phone: 863-688-2334 Fax: 863-577-0303 | |
Devashri Patel, Radiology Medicare: Accepting Medicare Assignments Practice Location: 1305 Lakeland Hills Blvd, Lakeland, FL 33805 Phone: 863-688-2334 | |
Jaehoon Bang, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1600 Lakeland Hills Blvd, Lakeland, FL 33805 Phone: 863-680-7000 Fax: 866-264-8519 |